PT3495358T - Compostos heterocíclicos substituídos por amida úteis como moduladores de respostas de il-12, il-23 e/ou ifn-alfa - Google Patents
Compostos heterocíclicos substituídos por amida úteis como moduladores de respostas de il-12, il-23 e/ou ifn-alfaInfo
- Publication number
- PT3495358T PT3495358T PT181975509T PT18197550T PT3495358T PT 3495358 T PT3495358 T PT 3495358T PT 181975509 T PT181975509 T PT 181975509T PT 18197550 T PT18197550 T PT 18197550T PT 3495358 T PT3495358 T PT 3495358T
- Authority
- PT
- Portugal
- Prior art keywords
- modulators
- amide
- substituted heterocyclic
- heterocyclic compounds
- compounds useful
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epidemiology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261723840P | 2012-11-08 | 2012-11-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3495358T true PT3495358T (pt) | 2022-06-02 |
Family
ID=49876960
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT181975509T PT3495358T (pt) | 2012-11-08 | 2013-11-07 | Compostos heterocíclicos substituídos por amida úteis como moduladores de respostas de il-12, il-23 e/ou ifn-alfa |
| PT13811640T PT2922846T (pt) | 2012-11-08 | 2013-11-07 | Compostos heterocíclicos substituídos por amida úteis como moduladores de il-12, il-23 e/ou ie'n-alfa |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT13811640T PT2922846T (pt) | 2012-11-08 | 2013-11-07 | Compostos heterocíclicos substituídos por amida úteis como moduladores de il-12, il-23 e/ou ie'n-alfa |
Country Status (39)
Families Citing this family (115)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20150944A1 (es) * | 2012-11-08 | 2015-06-20 | Bristol Myers Squibb Co | COMPUESTOS HETEROCICLICOS SUSTITUIDOS CON AMIDA UTILES COMO MODULADORES DE LAS RESPUESTAS DE INTERLEUCINA 12(IL-12), INTERLEUCINA 23 (IL-23) Y/O INTERFERON ALFA (IFN(alfa)) |
| EP2917186B1 (en) | 2012-11-08 | 2017-10-18 | Bristol-Myers Squibb Company | Alkyl amide-substituted pyrimidine compounds useful in the modulation of il-12, il-23 and/or ifn |
| AR094537A1 (es) | 2013-11-07 | 2015-08-12 | Bristol Myers Squibb Co | COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa |
| CN105992768B (zh) | 2013-12-10 | 2018-04-20 | 百时美施贵宝公司 | 用作IL‑12、IL‑23和/或IFNα响应的调节剂的咪唑并哒嗪化合物 |
| WO2015123453A1 (en) * | 2014-02-14 | 2015-08-20 | Portola Pharmaceuticals, Inc. | Pyridazine compounds as jak inhibitors |
| US10570096B2 (en) * | 2015-11-26 | 2020-02-25 | Novartis Ag | Diamino pyridine derivatives |
| TWI825663B (zh) | 2016-10-14 | 2023-12-11 | 美商林伯士拉克許米公司 | Tyk2抑制劑及其用途 |
| IL266109B2 (en) | 2016-10-21 | 2025-05-01 | Nimbus Lakshmi Inc | Tyk2 inhibitors and uses thereof |
| TW201827423A (zh) * | 2016-12-13 | 2018-08-01 | 美商必治妥美雅史谷比公司 | 做為IL-12, IL-23及/或IFNα反應調節劑之經烷基醯胺取代之雜芳基化合物氧化膦 |
| JOP20180011A1 (ar) | 2017-02-16 | 2019-01-30 | Gilead Sciences Inc | مشتقات بيرولو [1، 2-b]بيريدازين |
| TW202515876A (zh) | 2017-03-08 | 2025-04-16 | 日商武田藥品工業股份有限公司 | Tyk2抑制劑及其用途 |
| CN110475774B (zh) * | 2017-03-30 | 2023-06-02 | 百时美施贵宝公司 | 用于制备Tyk2抑制剂的方法 |
| SG11202004592TA (en) * | 2017-11-21 | 2020-06-29 | Bristol Myers Squibb Co | Sulfone pyridine alkyl amide-substituted heteroaryl compounds |
| JP6557436B1 (ja) | 2018-03-12 | 2019-08-07 | アッヴィ・インコーポレイテッド | チロシンキナーゼ２媒介性シグナル伝達の阻害剤 |
| ES2944733T3 (es) * | 2018-03-22 | 2023-06-23 | Bristol Myers Squibb Co | Compuestos heterocíclicos que comprenden piridina, útiles como moduladores de las respuestas a IL-12, IL-23 y/o IFN alfa |
| EP3810599A1 (en) * | 2018-05-31 | 2021-04-28 | Bristol-Myers Squibb Company | Crystalline form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3) pyridazine-3-carboxamide |
| TWI898556B (zh) | 2018-07-13 | 2025-09-21 | 美商基利科學股份有限公司 | 吡咯并[1,2-b]嗒衍生物 |
| GB201816369D0 (en) | 2018-10-08 | 2018-11-28 | Sareum Ltd | Pharmaceutical compounds |
| EP3866789A4 (en) | 2018-10-15 | 2022-07-06 | Nimbus Lakshmi, Inc. | TYK2 INHIBITORS AND USES THEREOF |
| SG11202104017VA (en) | 2018-10-22 | 2021-05-28 | Esker Therapeutics Inc | Tyk2 inhibitors and uses thereof |
| SG11202104307VA (en) * | 2018-10-30 | 2021-05-28 | Bristol Myers Squibb Co | Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of il-12, il-23 and/or ifn-alpha |
| EP3886843A4 (en) | 2018-11-30 | 2022-08-31 | Nimbus Lakshmi, Inc. | TYK2 INHIBITORS AND USES THEREOF |
| US11174264B2 (en) | 2019-01-23 | 2021-11-16 | Nimbus Lakshmi, Inc. | TYK2 inhibitors and uses thereof |
| CN117263918A (zh) * | 2019-01-28 | 2023-12-22 | 江苏豪森药业集团有限公司 | 一种哒嗪类衍生物抑制剂、其制备方法和应用 |
| CN111484480B (zh) * | 2019-01-29 | 2023-08-11 | 上海翰森生物医药科技有限公司 | 一种多环类衍生物抑制剂、其制备方法和应用 |
| KR20210121140A (ko) * | 2019-01-30 | 2021-10-07 | 브리스톨-마이어스 스큅 컴퍼니 | 아미드-이치환된 피리딘 또는 피리다진 화합물 |
| WO2020222773A1 (en) * | 2019-04-30 | 2020-11-05 | Celgene Corporation | Combination therapies comprising apremilast and tyk2 inhibitors |
| US11357775B2 (en) | 2019-04-30 | 2022-06-14 | Celgene Corporation | Combination therapies comprising apremilast and Tyk2 inhibitors |
| US20220235039A1 (en) * | 2019-06-12 | 2022-07-28 | Bristol-Myers Squibb Company | Crystalline salt forms of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyld3) pyridazine-3-carboxamide |
| EP3999499B1 (en) | 2019-07-16 | 2024-09-04 | Bristol-Myers Squibb Company | Prodrugs in the modulation of interleukin |
| CN114728949B (zh) * | 2019-08-01 | 2024-11-12 | 曙方医药 | 作为激酶抑制剂的杂环化合物及其用途 |
| US12215105B2 (en) | 2019-09-13 | 2025-02-04 | Nimbus Saturn, Inc. | HPK1 antagonists and uses thereof |
| JP7719770B2 (ja) * | 2019-09-18 | 2025-08-06 | ブリストル－マイヤーズ スクイブ カンパニー | Ｔｙｋ２阻害薬の徐放性剤形 |
| WO2021129467A1 (zh) * | 2019-12-27 | 2021-07-01 | 苏州科睿思制药有限公司 | 一种bms-986165晶型及其制备方法和用途 |
| WO2021143430A1 (zh) * | 2020-01-19 | 2021-07-22 | 苏州科睿思制药有限公司 | 一种bms-986165盐酸盐晶型及其制备方法和用途 |
| WO2021143498A1 (zh) * | 2020-01-19 | 2021-07-22 | 苏州科睿思制药有限公司 | 一种Deucravacitinib的晶型及其制备方法和用途 |
| US20230159520A1 (en) * | 2020-02-26 | 2023-05-25 | Beigene, Ltd. | Tyk-2 inhibitor |
| RS65506B1 (sr) | 2020-03-11 | 2024-06-28 | Beijing Innocare Pharma Tech Co Ltd | Heterociklična jedinjenja za inhibiciju aktivnosti tyk2 |
| WO2021204626A1 (en) * | 2020-04-06 | 2021-10-14 | Almirall, S.A. | Aryl and heteroaryl-carboxamide substituted heteroaryl compounds as tyk2 inhibitors |
| GB202005114D0 (en) | 2020-04-07 | 2020-05-20 | Sareum Ltd | Crystalline Forms of a Pharmaceutical Compound |
| CN113563309B (zh) * | 2020-04-28 | 2024-12-13 | 浙江海正药业股份有限公司 | 吡啶类衍生物及其制备方法和用途 |
| WO2021222153A1 (en) * | 2020-04-28 | 2021-11-04 | Bristol-Myers Squibb Company | Substituted n-(methyl-d3)pyridazine-3-carboxamide or n-(methyl-d3)-nicotinamide compounds as il-12, il-23 and/or ifnalpha modulators |
| CN113735837B (zh) * | 2020-05-28 | 2023-09-01 | 江苏先声药业有限公司 | 哒嗪类化合物及其用途 |
| CN113735836B (zh) * | 2020-05-28 | 2023-05-30 | 江苏先声药业有限公司 | 哒嗪类化合物及其应用 |
| CN113773262B (zh) * | 2020-06-09 | 2024-08-09 | 江苏先声药业有限公司 | 哒嗪类化合物 |
| CN115715288B (zh) | 2020-06-22 | 2025-11-25 | 百济神州有限公司 | Tyk-2抑制剂 |
| WO2022017494A1 (zh) * | 2020-07-24 | 2022-01-27 | 上海翰森生物医药科技有限公司 | 一种哒嗪类衍生物自由碱的晶型及其制备方法和应用 |
| CN113968846A (zh) * | 2020-07-24 | 2022-01-25 | 上海翰森生物医药科技有限公司 | 一种哒嗪类衍生物的盐、晶型及其制备方法和应用 |
| EP3944859A1 (en) | 2020-07-30 | 2022-02-02 | Assistance Publique Hôpitaux de Paris | Method for treating immune toxicities induced by immune checkpoint inhibitors |
| WO2022021684A1 (zh) * | 2020-07-31 | 2022-02-03 | 苏州科睿思制药有限公司 | 一种bms-986165盐酸盐晶型csv及其制备方法和用途 |
| CN114057651B (zh) * | 2020-07-31 | 2025-05-27 | 正大天晴药业集团股份有限公司 | 含酰胺基的tyk2抑制剂化合物 |
| AU2021342517A1 (en) | 2020-09-18 | 2023-05-11 | Bristol-Myers Squibb Company | Dosage forms for tyk2 inhibitors comprising swellable cores |
| WO2022083649A1 (zh) * | 2020-10-20 | 2022-04-28 | 杭州领业医药科技有限公司 | 哒嗪衍生物的晶型 |
| TW202233612A (zh) | 2020-10-23 | 2022-09-01 | 美商林伯士科羅索公司 | Ctps1抑制劑及其用途 |
| WO2022100710A1 (en) * | 2020-11-12 | 2022-05-19 | Cullgen (Shanghai) , Inc. | Tyrosine kinase 2 (tyk2) degradation compounds and methods of use |
| TW202227430A (zh) * | 2020-11-17 | 2022-07-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 含氮雜環類衍生物、其製備方法及其在醫藥上的應用 |
| CN116547276A (zh) * | 2020-12-08 | 2023-08-04 | 正大天晴药业集团股份有限公司 | 含酰胺基和杂环烷基的tyk2抑制剂化合物 |
| CN114981262A (zh) | 2020-12-22 | 2022-08-30 | 益方生物科技(上海)股份有限公司 | 杂芳基化合物及其制备方法和用途 |
| US12129245B2 (en) | 2021-01-29 | 2024-10-29 | Bristol-Myers Squibb Company | Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3) pyridazine-3-carboxamide |
| JP2024506858A (ja) | 2021-02-02 | 2024-02-15 | リミナル・バイオサイエンシーズ・リミテッド | Ｇｐｒ８４アンタゴニストおよびその使用 |
| EP4288427A1 (en) | 2021-02-02 | 2023-12-13 | Liminal Biosciences Limited | Gpr84 antagonists and uses thereof |
| TW202233600A (zh) * | 2021-02-06 | 2022-09-01 | 大陸商正大天晴藥業集團股份有限公司 | 含聯環的ｔｙｋ２抑制劑化合物、藥物組合物及其用途 |
| CN114907326B (zh) * | 2021-02-06 | 2025-02-18 | 正大天晴药业集团股份有限公司 | 含酰胺基和联环的tyk2抑制剂化合物 |
| EP4291235A4 (en) | 2021-02-12 | 2025-01-08 | Nimbus Saturn, Inc. | HPK1 ANTAGONISTS AND USES THEREOF |
| WO2022175752A1 (en) | 2021-02-19 | 2022-08-25 | Sudo Biosciences Limited | Tyk2 inhibitors and uses thereof |
| WO2022175747A1 (en) | 2021-02-19 | 2022-08-25 | Sudo Biosciences Limited | Tyk2 inhibitors and uses thereof |
| JP2024509192A (ja) | 2021-03-05 | 2024-02-29 | ニンバス サターン， インコーポレイテッド | Ｈｐｋ１アンタゴニスト及びその使用 |
| CA3213816A1 (en) * | 2021-03-16 | 2022-09-22 | Anrui Biomedical Technology (Guangzhou) Co., Ltd. | Amino heteroaryl compounds and compositions |
| KR20230163469A (ko) | 2021-03-29 | 2023-11-30 | 브리스톨-마이어스 스큅 컴퍼니 | 6-(시클로프로판카르복스아미도)-4-((2-메톡시-3-(1-메틸-1h-1,2,4-트리아졸-3-일)페닐)아미노)-n-(메틸-d3)피리다진-3-카르복스아미드의 결정 형태 |
| US12071442B2 (en) | 2021-03-29 | 2024-08-27 | Nimbus Saturn, Inc. | Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists |
| CN117177960B (zh) * | 2021-03-30 | 2025-01-28 | 浙江文达医药科技有限公司 | 作为tyk2假激酶结构域抑制剂的杂环化合物及合成方法和用途 |
| CN115197196B (zh) * | 2021-04-06 | 2024-06-18 | 扬子江药业集团有限公司 | Tyk2抑制剂及其用途 |
| BR112023020781A2 (pt) | 2021-04-09 | 2023-12-19 | Nimbus Clio Inc | Moduladores de cbl-b e usos dos mesmos |
| US20240382477A1 (en) * | 2021-05-04 | 2024-11-21 | Shanghai Zheye Biotechnology Co. Ltd. | Nitrogen-containing heterocyclic pyridine compound |
| US20240317718A1 (en) | 2021-05-14 | 2024-09-26 | Bristol-Myers Squibb Company | Substituted heterocyclic compounds |
| JP2024518792A (ja) | 2021-05-14 | 2024-05-02 | ブリストル－マイヤーズ スクイブ カンパニー | 置換ヘテロ環化合物 |
| JP2024518791A (ja) * | 2021-05-14 | 2024-05-02 | ブリストル－マイヤーズ スクイブ カンパニー | 置換ヘテロ環化合物 |
| CA3217332A1 (en) * | 2021-05-14 | 2022-11-17 | Bristol-Myers Squibb Company | Substituted heterocyclic compounds |
| WO2022253335A1 (zh) * | 2021-06-02 | 2022-12-08 | 南京明德新药研发有限公司 | 含磺酰基的芳基类化合物及其应用 |
| CN115466289A (zh) * | 2021-06-11 | 2022-12-13 | 爱科诺生物医药(香港)有限公司 | 具有tyk2抑制活性的化合物，包含其的药物组合物，及其应用 |
| KR20240024906A (ko) * | 2021-06-22 | 2024-02-26 | 메드샤인 디스커버리 아이엔씨. | 설폭시민 화합물 및 이의 용도 |
| WO2023284869A1 (zh) * | 2021-07-15 | 2023-01-19 | 南京明德新药研发有限公司 | 含硫/磷的芳基类化合物及其应用 |
| EP4387968B1 (en) * | 2021-08-20 | 2025-11-12 | Bristol-Myers Squibb Company | Crystal forms of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide |
| US20240368122A1 (en) * | 2021-08-21 | 2024-11-07 | Relay Therapeutics, Inc. | Jak2 inhibitors and methods of use thereof |
| CA3232812A1 (en) | 2021-09-23 | 2023-03-30 | Ian MacQuarie CATLETT | Methods of treating hair-loss disorders with tyk2 inhibitors |
| EP4408527A2 (en) | 2021-09-30 | 2024-08-07 | Bristol-Myers Squibb Company | Methods for determining responsiveness to tyk2 inhibitors |
| EP4423086A1 (en) | 2021-10-25 | 2024-09-04 | Kymera Therapeutics, Inc. | Tyk2 degraders and uses thereof |
| WO2023076515A1 (en) | 2021-10-28 | 2023-05-04 | Bristol-Myers Squibb Company | Topical formulations of deucravacitinib |
| WO2023102085A1 (en) | 2021-12-01 | 2023-06-08 | Teva Czech Industries S.R.O. | Solid state forms of deucravacitinib, deucravacitinib hcl and process for preparation of deucravacitinib and intermediates |
| IL313571A (en) * | 2021-12-16 | 2024-08-01 | Lynk Pharmaceuticals Co Ltd | Tyk2 inhibitors and compositions and methods thereof |
| WO2023108536A1 (en) * | 2021-12-16 | 2023-06-22 | Lynk Pharmaceuticals Co. Ltd. | Tyk2 inhibitors and compositions and methods thereof |
| CN116283928A (zh) * | 2021-12-20 | 2023-06-23 | 艾立康药业股份有限公司 | 一种哒嗪类化合物、其制备方法和应用 |
| EP4206196A1 (en) | 2021-12-29 | 2023-07-05 | Almirall S.A. | Pyrimidine substituted derivatives as tyk2 inhibitors |
| CN116693449A (zh) * | 2022-03-04 | 2023-09-05 | 上海致根医药科技有限公司 | 用作tyk2抑制剂的化合物、其制备方法及其在医药上的应用 |
| CN119233971A (zh) * | 2022-05-31 | 2024-12-31 | 上海华汇拓医药科技有限公司 | 一种哒嗪类化合物、其制备方法和用途 |
| WO2024020221A1 (en) | 2022-07-21 | 2024-01-25 | Arvinas Operations, Inc. | Modulators of tyk2 proteolysis and associated methods of use |
| CA3263151A1 (en) | 2022-08-02 | 2024-02-08 | Liminal Biosciences Ltd | HETEROARYL-CARBOXAMIDE AND ASSOCIATED GPR84 ANTAGONISTS AND THEIR USES |
| CA3263154A1 (en) | 2022-08-02 | 2024-02-08 | Liminal Biosciences Ltd | ARYL-TRIAZOLYL AND RELATED GPR84 ANTAGONISTS AND THEIR USES |
| EP4565564A1 (en) | 2022-08-02 | 2025-06-11 | Liminal Biosciences Limited | Substituted pyridone gpr84 antagonists and uses thereof |
| KR20250099236A (ko) | 2022-11-08 | 2025-07-01 | 브리스톨-마이어스 스큅 컴퍼니 | 치환된 헤테로시클릭 화합물 |
| AR131375A1 (es) | 2022-12-16 | 2025-03-12 | Alembic Pharmaceuticals Ltd | Ligandos de pseudoquinasa tyk2 y sus usos |
| CN116284040B (zh) * | 2023-01-05 | 2024-05-28 | 华润医药研究院（深圳）有限公司 | 含氮杂环类化合物及其医药用途 |
| CN120693328A (zh) * | 2023-02-07 | 2025-09-23 | 浙江华海药业股份有限公司 | 一种哒嗪类化合物、其制备方法和用途 |
| CN118724752B (zh) * | 2023-03-29 | 2025-11-28 | 重庆博腾制药科技股份有限公司 | 一种酪氨酸激酶抑制剂中间体、制备方法及其应用 |
| CN116162093B (zh) * | 2023-04-25 | 2023-06-23 | 中南大学湘雅医院 | 一种tyk2抑制剂化合物及其用途 |
| WO2024236491A1 (en) * | 2023-05-15 | 2024-11-21 | Glenmark Life Sciences Limited | Process for the preparation of deucravacitinib, and crystalline forms thereof |
| CN119080742A (zh) * | 2023-06-05 | 2024-12-06 | 甘莱制药有限公司 | 脂质合成的杂环调节剂的工业化制备 |
| WO2024257023A1 (en) | 2023-06-14 | 2024-12-19 | Alembic Pharmaceuticals Limited | Tyk2 pseudokinase ligands and uses thereof |
| CN117447353A (zh) * | 2023-09-21 | 2024-01-26 | 爱斯特（成都）生物制药股份有限公司 | 一种氘可来昔替尼中间体的制备方法 |
| WO2025062372A1 (en) | 2023-09-21 | 2025-03-27 | Takeda Pharmaceutical Company Limited | Tyk2 inhibitors for use in the treatment of inflammatory bowel disease |
| EP4538259A1 (en) | 2023-10-09 | 2025-04-16 | Farmhispania Group, S.L. | Processes for the preparation of deucravacitinib |
| WO2025131031A1 (zh) * | 2023-12-22 | 2025-06-26 | 上海奥博生物医药股份有限公司 | 一种TyK2抑制剂及其中间体的制备方法 |
| WO2025186427A1 (en) | 2024-03-08 | 2025-09-12 | Curia Spain, S.A.U. | Process for the preparation of deucravacitinib and intermediates thereof and method for purifying deucravacitinib |
| CN118593504B (zh) * | 2024-06-03 | 2025-03-18 | 北京大学第三医院（北京大学第三临床医学院） | 氘可来昔替尼或其盐在制备pvns药物方面的新用途 |
| CN119059972B (zh) * | 2024-08-12 | 2025-10-28 | 武汉九州钰民医药科技有限公司 | 一种btk抑制剂吡托布鲁替尼的合成方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4622047B2 (ja) * | 1999-06-09 | 2011-02-02 | アステラス製薬株式会社 | 新規なヘテロ環カルボキサミド誘導体 |
| ATE288420T1 (de) | 1999-06-09 | 2005-02-15 | Yamanouchi Pharma Co Ltd | Neuartige heterocyclische carboxamid-derivate |
| WO2000076980A1 (en) * | 1999-06-10 | 2000-12-21 | Yamanouchi Pharmaceutical Co., Ltd. | Novel nitrogen-contaiing heterocyclic derivatives or salts thereof |
| US7273868B2 (en) | 2000-04-28 | 2007-09-25 | Tanabe Seiyaku Co., Ltd. | Pyrazine derivatives |
| CA2356544C (en) | 2000-10-03 | 2006-04-04 | Warner-Lambert Company | Pyridotriazines and pyridopyridazines |
| AU2003251900B2 (en) | 2002-07-15 | 2008-12-18 | President And Fellows Of Harvard College | Methods and compositions for modulating T helper (Th) cell development and function |
| US7176214B2 (en) | 2003-05-21 | 2007-02-13 | Bristol-Myers Squibb Company | Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same |
| EP2547338A2 (en) | 2010-03-17 | 2013-01-23 | F. Hoffmann-La Roche AG | Imidazopyridine compounds, compositions and methods of use |
| RU2013114352A (ru) | 2010-09-15 | 2014-10-20 | Ф. Хоффманн-Ля Рош Аг | Азабензотиазолы, композиции и способы применения |
| EP2640722B1 (en) | 2010-11-19 | 2015-11-04 | F.Hoffmann-La Roche Ag | Pyrazolopyridines and their use as tyk2 inhibitors |
| WO2013047813A1 (ja) * | 2011-09-30 | 2013-04-04 | 大鵬薬品工業株式会社 | １，２，４－トリアジン－６－カルボキサミド誘導体 |
| EP2802567B1 (en) * | 2012-01-10 | 2017-03-01 | F. Hoffmann-La Roche AG | Pyridazine amide compounds and their use as syk inhibitors |
| UY34807A (es) * | 2012-05-16 | 2013-12-31 | Novartis Ag | Derivados monocíclicos de heteroarilcicloalquil- diamina |
| US9040530B2 (en) * | 2012-06-22 | 2015-05-26 | Portola Pharmaceuticals, Inc. | 1,2,4-triazine-6-carboxamide kinase inhibitors |
| RU2015116532A (ru) * | 2012-10-19 | 2016-12-10 | Ф. Хоффманн-Ля Рош Аг | Ингибиторы тирозинкиназы syk |
| PE20150944A1 (es) * | 2012-11-08 | 2015-06-20 | Bristol Myers Squibb Co | COMPUESTOS HETEROCICLICOS SUSTITUIDOS CON AMIDA UTILES COMO MODULADORES DE LAS RESPUESTAS DE INTERLEUCINA 12(IL-12), INTERLEUCINA 23 (IL-23) Y/O INTERFERON ALFA (IFN(alfa)) |
| EP2917186B1 (en) | 2012-11-08 | 2017-10-18 | Bristol-Myers Squibb Company | Alkyl amide-substituted pyrimidine compounds useful in the modulation of il-12, il-23 and/or ifn |
| MX2015005272A (es) | 2012-11-08 | 2015-07-14 | Squibb Bristol Myers Co | Compuestos de piridilo sustituidos con alquilamida utiles como moduladores de las respuestas de interleucina 12 (il-12), interleucina 23 (il-23) y/o interferon alfa (ifnalfa). |
| AR094537A1 (es) * | 2013-11-07 | 2015-08-12 | Bristol Myers Squibb Co | COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa |
| CN110475774B (zh) | 2017-03-30 | 2023-06-02 | 百时美施贵宝公司 | 用于制备Tyk2抑制剂的方法 |
-
2013
- 2013-11-07 PE PE2015000607A patent/PE20150944A1/es active IP Right Grant
- 2013-11-07 EP EP13811640.5A patent/EP2922846B1/en active Active
- 2013-11-07 PT PT181975509T patent/PT3495358T/pt unknown
- 2013-11-07 HR HRP20220766TT patent/HRP20220766T1/hr unknown
- 2013-11-07 LT LTEP13811640.5T patent/LT2922846T/lt unknown
- 2013-11-07 NZ NZ708859A patent/NZ708859A/en unknown
- 2013-11-07 EP EP18197550.9A patent/EP3495358B8/en active Active
- 2013-11-07 CN CN201380069692.9A patent/CN104884454B/zh active Active
- 2013-11-07 EA EA201590917A patent/EA028814B1/ru not_active IP Right Cessation
- 2013-11-07 TW TW102140572A patent/TWI605041B/zh active
- 2013-11-07 US US14/441,183 patent/US9505748B2/en not_active Ceased
- 2013-11-07 SI SI201331219T patent/SI2922846T1/sl unknown
- 2013-11-07 JP JP2015541883A patent/JP6407159B2/ja active Active
- 2013-11-07 AU AU2013341186A patent/AU2013341186B2/en active Active
- 2013-11-07 SG SG10201706985UA patent/SG10201706985UA/en unknown
- 2013-11-07 SI SI201331986T patent/SI3495358T1/sl unknown
- 2013-11-07 SG SG10201706897TA patent/SG10201706897TA/en unknown
- 2013-11-07 PL PL18197550T patent/PL3495358T3/pl unknown
- 2013-11-07 UY UY0001035126A patent/UY35126A/es unknown
- 2013-11-07 BR BR112015010102-0A patent/BR112015010102B1/pt active IP Right Grant
- 2013-11-07 PL PL13811640T patent/PL2922846T3/pl unknown
- 2013-11-07 MY MYPI2022004735A patent/MY198262A/en unknown
- 2013-11-07 PT PT13811640T patent/PT2922846T/pt unknown
- 2013-11-07 HR HRP20181937TT patent/HRP20181937T1/hr unknown
- 2013-11-07 MY MYPI2020005025A patent/MY194668A/en unknown
- 2013-11-07 TR TR2018/20824T patent/TR201820824T4/tr unknown
- 2013-11-07 MY MYPI2015701475A patent/MY175448A/en unknown
- 2013-11-07 WO PCT/US2013/068846 patent/WO2014074661A1/en not_active Ceased
- 2013-11-07 ES ES18197550T patent/ES2914793T3/es active Active
- 2013-11-07 HU HUE18197550A patent/HUE059409T2/hu unknown
- 2013-11-07 RS RS20181428A patent/RS58187B1/sr unknown
- 2013-11-07 EP EP22165094.8A patent/EP4071144A1/en active Pending
- 2013-11-07 AR ARP130104091A patent/AR094452A1/es active IP Right Grant
- 2013-11-07 MA MA38072A patent/MA38072A1/fr unknown
- 2013-11-07 SM SM20220258T patent/SMT202200258T1/it unknown
- 2013-11-07 LT LTEP18197550.9T patent/LT3495358T/lt unknown
- 2013-11-07 MX MX2015005731A patent/MX2015005731A/es active IP Right Grant
- 2013-11-07 RS RS20220589A patent/RS63328B1/sr unknown
- 2013-11-07 US US16/201,653 patent/USRE47929E1/en active Active
- 2013-11-07 ES ES13811640T patent/ES2702148T3/es active Active
- 2013-11-07 CA CA2890981A patent/CA2890981C/en active Active
- 2013-11-07 SM SM20190001T patent/SMT201900001T1/it unknown
- 2013-11-07 SG SG11201503399XA patent/SG11201503399XA/en unknown
- 2013-11-07 DK DK18197550.9T patent/DK3495358T3/da active
- 2013-11-07 HU HUE13811640A patent/HUE041750T2/hu unknown
- 2013-11-07 KR KR1020157014694A patent/KR102195194B1/ko active Active
- 2013-11-07 DK DK13811640.5T patent/DK2922846T3/en active
-
2015
- 2015-05-04 IL IL238610A patent/IL238610A0/en active IP Right Grant
- 2015-05-06 MX MX2020003156A patent/MX2020003156A/es unknown
- 2015-05-06 PH PH12015501004A patent/PH12015501004A1/en unknown
- 2015-05-07 CL CL2015001231A patent/CL2015001231A1/es unknown
- 2015-06-05 ZA ZA2015/04052A patent/ZA201504052B/en unknown
-
2016
- 2016-10-10 US US15/289,437 patent/US10000480B2/en active Active
-
2017
- 2017-02-17 AU AU2017201076A patent/AU2017201076B2/en active Active
-
2018
- 2018-05-15 US US15/979,770 patent/US10526321B2/en active Active
- 2018-05-16 JP JP2018094837A patent/JP6585231B2/ja active Active
- 2018-11-19 AU AU2018267545A patent/AU2018267545B2/en active Active
- 2018-12-14 CY CY20181101343T patent/CY1121188T1/el unknown
-
2019
- 2019-09-04 JP JP2019161215A patent/JP2020002157A/ja active Pending
- 2019-11-18 US US16/687,279 patent/US11021475B2/en active Active
-
2020
- 2020-06-15 AU AU2020203967A patent/AU2020203967B2/en active Active
-
2021
- 2021-04-29 US US17/244,938 patent/US20220356180A1/en not_active Abandoned
-
2022
- 2022-06-02 CY CY20221100391T patent/CY1125220T1/el unknown
-
2023
- 2023-07-24 NL NL301238C patent/NL301238I2/nl unknown
- 2023-07-27 CY CY2023017C patent/CY2023017I2/el unknown
- 2023-08-10 HU HUS2300025C patent/HUS2300025I1/hu unknown
- 2023-08-14 FR FR23C1030C patent/FR23C1030I2/fr active Active
- 2023-08-23 LT LTPA2023523C patent/LTC2922846I2/lt unknown
- 2023-08-25 NO NO2023032C patent/NO2023032I1/no unknown
- 2023-08-28 FI FIC20230028C patent/FIC20230028I1/fi unknown
-
2024
- 2024-09-10 US US18/830,387 patent/US20250243193A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS2300025I1 (hu) | Amidszubsztituált heterociklikus vegyületek mint IL-12, IL-23 és/vagy IFN-ALFA modulátorai | |
| EP2922841B8 (en) | Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifn alpha responses | |
| IL245448B (en) | Alkyl-amide substituted pyridyl compounds useful as modulators of responses to il-12, il-23, and/or ifnalpha | |
| DK3628161T3 (da) | Synergistiske bakterielle sammensætninger og fremgangsmåder til fremstilling og anvendelse deraf | |
| SG11201501292UA (en) | Anxiolytic composition, formulation and method of use | |
| EP3054870A4 (en) | Compressed bone composition and methods of use thereof | |
| PT2988756T (pt) | Formulação de um meio de contraste e seu processo de preparação associado | |
| GB201301626D0 (en) | Composition comprising 15-OHEPA and methods of using the same | |
| WO2015081319A3 (en) | Activity enhancing curcumin compositions and methods of use | |
| EP2900916A4 (en) | STITCHING COLMATANT MATERIAL AND METHOD OF USE | |
| GB201307082D0 (en) | Pharmaceutical composition comprising 15-HETrE and methods of using the same | |
| ZA201502205B (en) | Ectoparasitic treatment method and composition | |
| AU2014318672B2 (en) | Recombinant microorganisms and methods of use thereof | |
| SMT201900406T1 (it) | Composti piridilici alchil-ammide-sostitidti utili come modulatori delle risposte di il-12, il-23 e/o ifn-alfa | |
| GB201207064D0 (en) | Pharmaceutical compositions comprising 15-hetre and methods of using the same | |
| AU2013902122A0 (en) | Ectoparasitic Treatment Method and Composition | |
| GB201310349D0 (en) | Composition and method of use thereof | |
| GB201301928D0 (en) | Composition and method of use thereof |